Advanced or metastatic dedifferentiated liposarcoma (DDLPS) is an aggressive subtype requiring active systemic management. Anthracycline-based therapy — as a single agent or combined with ifosfamide — represents the established front-line standard for metastatic DDLPS. When disease progresses beyond this initial approach, a structured second-line treatment strategy is indicated.
This protocol applies to patients with advanced or metastatic dedifferentiated liposarcoma who require systemic therapy in the second-line setting. Treatment choices in this situation are limited, making a structured, evidence-based approach especially important.
Second-line systemic chemotherapy options exist for this setting, involving specific agents — including both single-agent and combination regimens.
DOI: 10.1016/j.ctrv.2024.102846
Anthracycline-based therapy, either as a single agent (doxorubicin or epirubicin) or as part of a combination (doxorubicin or epirubicin in combination with ifosfamide), is considered the front-line standard for metastatic DDLPS.
Available second-line treatments include gemcitabine plus docetaxel, trabectedin, and eribulin.
Treatment options in the second and later lines of therapy for DDLPS remain limited and include gemcitabine-based regimens as well as trabectedin and eribulin.
View source ↗